Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan for sarcopenia in heart failure with reduced ejection fraction
ChiCTR2100041785Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Sarcopenia and heart failure with reduced ejection fraction (HFrEF) comparing Levosimendan group with Placebo group (2 arms). Primary endpoints: Disability rate, Rehospitalization rate and 1 more. Started Jul 2020; status: recruiting.
02
Drugs
levosimendan
03
Conditions
Sarcopeniaheart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR2100041785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041785.